{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:50:14Z","timestamp":1790812214646,"version":"4.1.0"},"reference-count":33,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,7,12]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Sitagliptin is a dipeptidyl peptidase-4 inhibitor commonly used in the treatment of type 2 diabetes mellitus for glycaemic control. Concerns have arisen regarding adverse events caused by this drug, particularly concerning arthralgias. Here, we report on a 56-year-old man being treated with sitagliptin who developed inflammatory arthritis after taking the drug for 6\u2009months. The patient presented with pain, swelling and erythema in multiple joints and was eventually diagnosed with seronegative rheumatoid arthritis (RA) under the 2010 American College of Rheumatology\/European League Against Rheumatism classification criteria. His symptoms continued for several months after stopping sitagliptin and eventually went into remission after a tapered course of steroids, hydroxychloroquine and methotrexate. Furthermore, the patient is HLA-DRB3 positive, a genetic marker that is still being investigated for its role in the pathogenesis of RA and that may have been a predisposing factor in the development of this patient\u2019s inflammatory arthropathy.<\/jats:p>","DOI":"10.1136\/bcr-2018-228981","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T04:45:23Z","timestamp":1566535523000},"page":"e228981","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis"],"prefix":"10.1136","volume":"12","author":[{"given":"Simonette","family":"Padron","sequence":"first","affiliation":[{"name":"Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett","family":"Rogers","sequence":"additional","affiliation":[{"name":"Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Demory Beckler","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Nova Southeastern University Health Professions Division, College of Medical Sciences, Fort Lauderdale, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kesselman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"2025082703332458000_12.8.e228981.1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3094642"},{"key":"2025082703332458000_12.8.e228981.2","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.diabres.2013.07.010","article-title":"Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors","volume":"102","author":"Saito","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"2025082703332458000_12.8.e228981.3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2169\/internalmedicine.51.7592","article-title":"Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report","volume":"51","author":"Yokota","year":"2012","journal-title":"Intern Med"},{"key":"2025082703332458000_12.8.e228981.4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/art.27395","article-title":"Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts","volume":"62","author":"Ospelt","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025082703332458000_12.8.e228981.5","doi-asserted-by":"publisher","DOI":"10.1016\/0885-4505(91)90016-E"},{"key":"2025082703332458000_12.8.e228981.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62266-3"},{"key":"2025082703332458000_12.8.e228981.7","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015 http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm459579.htm (Accessed Jan 2018)."},{"key":"2025082703332458000_12.8.e228981.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025082703332458000_12.8.e228981.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/257028","article-title":"Diabetic cheiroarthropathy: a case report and review of the literature","volume":"2013","author":"Cherqaoui","year":"2013","journal-title":"Case Rep Endocrinol"},{"key":"2025082703332458000_12.8.e228981.10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.11613\/BM.2013.033","article-title":"Diabetes and beta cell function: from mechanisms to evaluation and clinical implications","volume":"23","author":"Cernea","year":"2013","journal-title":"Biochem Med"},{"key":"2025082703332458000_12.8.e228981.11","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0396"},{"key":"2025082703332458000_12.8.e228981.12","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.suppl_2.S97"},{"key":"2025082703332458000_12.8.e228981.13","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.4049\/jimmunol.141.7.2325","article-title":"IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans","volume":"141","author":"Campbell","year":"1988","journal-title":"J Immunol"},{"key":"2025082703332458000_12.8.e228981.14","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1998.1004"},{"key":"2025082703332458000_12.8.e228981.15","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.suppl_2.S108"},{"key":"2025082703332458000_12.8.e228981.16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/22201009.2008.10872177","article-title":"The mechanism of action of oral antidiabetic drugs: a review of recent literature","volume":"13","author":"B\u00f6senberg","year":"2008","journal-title":"Journal of Endocrinology, Metabolism and Diabetes of South Africa"},{"key":"2025082703332458000_12.8.e228981.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.8.707"},{"key":"2025082703332458000_12.8.e228981.18","first-page":"335","article-title":"MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis","volume":"22","author":"Giannelli","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"2025082703332458000_12.8.e228981.19","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2003.095"},{"key":"2025082703332458000_12.8.e228981.20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40264-016-0399-8","article-title":"Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis\/Arthralgia: A Review of Clinical Cases","volume":"39","author":"Mascolo","year":"2016","journal-title":"Drug Saf"},{"key":"2025082703332458000_12.8.e228981.21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.3.1101"},{"key":"2025082703332458000_12.8.e228981.22","doi-asserted-by":"publisher","DOI":"10.1007\/s004280050472"},{"key":"2025082703332458000_12.8.e228981.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002098"},{"key":"2025082703332458000_12.8.e228981.24","doi-asserted-by":"publisher","DOI":"10.1186\/ar1852"},{"key":"2025082703332458000_12.8.e228981.25","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.4049\/jimmunol.154.7.3062","article-title":"Phenotypic characterization of CD4+ T cells that exhibit a transendothelial migratory capacity","volume":"154","author":"Brezinschek","year":"1995","journal-title":"J Immunol"},{"key":"2025082703332458000_12.8.e228981.26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.4049\/jimmunol.148.5.1367","article-title":"Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro","volume":"148","author":"Masuyama","year":"1992","journal-title":"J Immunol"},{"key":"2025082703332458000_12.8.e228981.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.8101391"},{"key":"2025082703332458000_12.8.e228981.28","unstructured":"OMIM. \u201cOnline mendelian inheritance in man \u2013 major histocompatibility complex, class I, A; HLA-A.\u201d. http:\/\/omim.org\/entry\/142800?search=6p21.3&highlight=6p213 (Accessed Jan 2018)."},{"key":"2025082703332458000_12.8.e228981.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.02.006"},{"key":"2025082703332458000_12.8.e228981.30","unstructured":"U S National Library of Medicine. Home - Gene - NCBI. 2008 www.ncbi.nlm.nih.gov\/gene?Db=gene (Accessed Jan 2018)."},{"key":"2025082703332458000_12.8.e228981.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.21302"},{"key":"2025082703332458000_12.8.e228981.32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/pds.3503","article-title":"Association of musculoskeletal complaints and gliptin use: review of spontaneous reports","volume":"22","author":"Tarapu\u00e9s","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025082703332458000_12.8.e228981.33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s13340-010-0010-y","article-title":"Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus","volume":"1","author":"Sasaki","year":"2010","journal-title":"Diabetol Int"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-228981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:33:37Z","timestamp":1756290817000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-228981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,22]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bcr-2018-228981"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-228981","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}